Passage Bio, Inc.
General ticker "PASG" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $27.6M (TTM average)
Passage Bio, Inc. follows the US Stock Market performance with the rate: 27.7%.
Estimated limits based on current volatility of 9.7%: low 13.36$, high 16.22$
Factors to consider:
- Total employees count: 27 (-53.4%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Product development risks, Acquisition/divestiture risks, Manufacturing risks, Strategic risks and growth management
- Current price 28.4% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.16$, 17.07$]
- 2025-12-31 to 2026-12-31 estimated range: [2.95$, 10.02$]
Financial Metrics affecting the PASG estimates:
- Negative: with PPE of -12.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -123.75 <= 0.04
- Negative: negative Net income
- Positive: 42.53 < Shareholder equity ratio, % of 59.82 <= 64.17
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 141.78 > -0.62
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PASG quotes
Long-term PASG plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $138.39MM | $108.39MM | $70.40MM |
| Operating Income | $-138.39MM | $-108.39MM | $-70.40MM |
| Non-Operating Income | $2.27MM | $6.33MM | $5.63MM |
| R&D Expense | $86.05MM | $61.42MM | $40.18MM |
| Income(Loss) | $-136.12MM | $-102.06MM | $-64.77MM |
| Profit(Loss)* | $-136.12MM | $-102.06MM | $-64.77MM |
| Stockholders Equity | $201.37MM | $111.28MM | $61.26MM |
| Assets | $243.55MM | $150.54MM | $102.41MM |
| Operating Cash Flow | $-118.21MM | $-78.26MM | $-47.96MM |
| Capital expenditure | $5.27MM | $0.15MM | $0.03MM |
| Investing Cash Flow | $25.20MM | $65.24MM | $54.95MM |
| Financing Cash Flow | $-1.35MM | $0.14MM | $8.87MM |
| Earnings Per Share** | $-50.02 | $-37.29 | $-21.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.